We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current BIM market cap is 12.01B. The company's latest EPS is EUR 3.0319 and P/E is 33.58.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 2.67B | 3.12B | 3.38B | 3.59B | 3.67B |
| Operating Income | 370.7M | 552.7M | 784.3M | 587.3M | 438.7M |
| Net Income | 272.8M | 404.4M | 601.1M | 452.4M | 357.6M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 3.78B | 3.93B | 4.61B | 5.19B | 5.26B |
| Total Liabilities | 1.53B | 1.45B | 1.44B | 1.54B | 1.51B |
| Total Equity | 2.25B | 2.48B | 3.16B | 3.64B | 3.75B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 407.9M | 582.8M | 824.7M | 475.1M | 445.5M |
| Investing | -282.2M | -265.2M | -307.3M | -528.1M | -488.8M |
| Financing | -133.9M | -176.2M | -140.6M | -244.3M | -122.3M |
| Market Cap | 12.01B |
| Price to Earnings Ratio | 33.58 |
| Price to Sales Ratio | 3.27 |
| Price to Cash Ratio | 34.07 |
| Price to Book Ratio | 3.2 |
| Dividend Yield | 0.83% |
| Shares Outstanding | 117.95M |
| Average Volume (1 week) | 112.62k |
| Average Volume (1 Month) | 94.73k |
| 52 Week Change | 0.89% |
| 52 Week High | 111.50 |
| 52 Week Low | 88.25 |
| Spread (Intraday) | 0.2 (0.2%) |
| Company Name | Biomerieux |
| Address |
chemin de l'orme lyon, rhone 69280 |
| Website | https://www.biomerieux.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
